Infliximab for the treatment of active scleritis

Canadian Journal of Ophthalmology

Volumn 44, Issue 3, 2009, Pages e9-

  Sen, H Nida ^a   Sangave, Amit ^a   Hammel, Keri ^b   Levy Clarke, Grace ^a   Nussenblatt, Robert B ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b EMMES CORPORATION   (United States)

Author keywords

Immunosuppressive therapy; Infliximab; Scleritis; TNF

Indexed keywords

INFLIXIMAB; METHOTREXATE; PREDNISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EAR INFECTION; EYE INFLAMMATION; FACE RASH; FEMALE; HEADACHE; HEARING IMPAIRMENT; HUMAN; IRIDOCYCLITIS; LOWER RESPIRATORY TRACT INFECTION; MALE; MOUTH INFLAMMATION; NOSE CONGESTION; PARESTHESIA; SCLERA DISEASE; SKIN TINGLING; TREATMENT OUTCOME; TREMOR; URINARY TRACT INFECTION;

EID: 66749098904     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/i09-061     Document Type: Article

References (25)

1. McCluskey PJ, Wakefield D. Scleritis and episcleritis. In: Pepose JS, Holland GN, Wilhelmus KR, eds. Ocular Infection and Immunity. St. Louis, Mo.: Mosby-Year Book Inc; 1996;642-661
2. Nussenblatt RB. The natural history of uveitis. Int Ophthalmol 1990;14:303-308 (Pubitemid 20350862)
3. Hakin KN, Ham J, Lightman SL. Use of cyclosporin in the management of steroid dependent non-necrotising scleritis. Br J Ophthalmol 1991;75:340-341
4. Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmohgy 1984;91:1253-1263 (Pubitemid 15203402)
5. Shah SS, Lowder CY, Schmitt MA, Wilke WS, Kosmorsky GS, Meisler DM. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 1992;99:1419-1423
6. Sen HN, Suhler EB, Al-Khatib SQ, Djalilian AR, Nussenblatt RB, Buggage RR. Mycophenolate mofetil for the treatment of scleritis. Ophthalmohgy 2003;110:1750-1755 (Pubitemid 37025434)
7. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000;130:492-513.
8. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903-912 (Pubitemid 41057986)
9. Martin TM, Smith JR, Rosenbaum JT. Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies. Curr Opin Rheumatol 2002;14:337-341 (Pubitemid 34693974)
10. Di Girolamo N, Visvanathan K, Lloyd A, Wakefield D. Expression of TNF-alpha by human plasma cells in chronic inflammation. J Leukoc Biol 1997;61:667-678 (Pubitemid 27276058)
11. Seo KY, Lee HK, Kim EK, Lee JH. Expression of tumor necrosis factor alpha and matrix metalloproteinase-9 in surgically induced necrotizing scleritis. Ophthalmic Res 2006;38:66-70. (Pubitemid 43325896)
12. Murphy CC, Greiner K, Plskova J, et al. Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch Ophthalmol 2004;122:845-851 (Pubitemid 38736243)
13. Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmohgy 2004;111:352-356 (Pubitemid 38183244)
14. Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003;110:1449-1453 (Pubitemid 36842488)
15. El-Shabrawi Y, Hermann J. Anti-TNF alpha therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener's granulomatosis. Eye 2005;19:1017-1018 (Pubitemid 43114989)
16. Buggage RR, Levy-Clarke G, Sen HN, et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Ocul Immunol Inflamm 2007;15:63-70. (Pubitemid 46897689)
17. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-516
18. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-1453 (Pubitemid 23356004)
19. Hommes DW, Oldenburg B, van Bodegraven AA, et al. Guidelines for treatment with infliximab for Crohn's disease. Neth J Med 2006;64-219-229 (Pubitemid 44203651)
20. Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 2004;138:648-650
21. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med 2004;140:404-406 (Pubitemid 38268925)
22. El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 2002;109:2342-2346 (Pubitemid 35417121)
23. Mascheretti S, Hampe J, Kühbacher T, et al. Pharmacogenetic investigation of theTNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J 2002;2:127-136 (Pubitemid 34982216)
24. Pierik M, Vermeire S, Steen KV, et al. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther 2004;20:303-310 (Pubitemid 39062133)
25. Eklund KK, Peltomaa R, Leirisalo-Repo M. Occurrence of pulmonary thromboembolism during infliximab therapy. Clin Exp Rheumatol 2003;21:679. (Pubitemid 37236473)